Influence of efflux transporters on the intestinal passage of drugs;Influence des transporteurs d'efflux sur le passage intestinal des médicaments

Revue Francaise des Laboratoires

Volumn 2002, Issue 339, 2002, Pages 33-37

  Cornaire, Gilles ^a   Woodley, John F ^a   Houin, Georges ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CHU RANGUEIL   (France)

Author keywords

Intestinal absorption; Multidrug resistance associated protein (MRP); P glycoprotein; Pharmacokinetic interactions

Indexed keywords

EID: 23444444183     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0338-9898(02)80138-X     Document Type: Article

References (32)

1. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan, I., Gottesman M.M., Biochemical, cellular, and pharmacological aspects of the multi-drug transporter, Ann. Rev. Pharmacol. Toxicol. 39 (1999) 361-398.
2. Barthe L., Bessouet M., Woodley J.F., Houin G., The improved everted gut sac: a simple method to study intestinal P-glycoprotein, Int. J. Pharm. 173 (1998) 255-258.
3. Barthe L., Woodley J.F., Kenworthy S., Houin G., An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine, Eur. J. Drug Metab. Pharmacokinet. 23 (2) (1998) 313-323.
4. Benet L.Z., Izumi T., Zhang Y., Silverman J.A., Wacher V.J., Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery, J. Cont. Rel. 62 (1-2) (1999) 25-31.
5. Bolhuis H., Veen Van H.W., Poolman B., Driessen A.J.M., Konings W.N., Mechanisms of multi-drug transporters, FEMS Microbiol. Rev. 21 (1997) 55-84.
6. Bouer R., Barthe L., Philibert C., Tournaire C., Woodley J., Houin G., The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac, Fundam. Clin. Pharmacol. 13 (4) (1999) 494-500.
7. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol. 40 (1) (2000) 91-98.
8. Burton P.S., Goodwin T.J., Conradi R.A., Ho N.F.H., Hilgers A.R., In vitro permeability of peptidomimetic drugs: the role of polarized efflux pathways as additional barriers to absorption, Adv. Drug Deliv. Rev. 23 (1997) 143-156.
9. Carreno-Gomez B., Duncan R., Everted rat intestinal sacs: a new model for the quantitation of P-glycoprotein mediated-efflux of anticancer agents, Anticancer Res. 20 (5A) (2000) 3157-3161.
10. Cormet-Boyaka E., Huneau J.F., Mordrelle A., Boyaka P.N., Carbon C., Rubinstein E., Tome D., Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors, Antimicob. Agents Chemother. 42 (10) (1998) 2607-2611.
11. Cornaire G., Woodley J.F., Saivin S., Legendre J.-Y., Decourt S., Cloarec A., Houin G., Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro, Arzneim.-Forsch./Drug Res. 50 (1) (2000) 576-579.
12. Del Moral R.G., Olmo A., Aguilar M., P-glycoprotein: a new mechanism to control drug-induced nephrotoxicity, Exp. Nephrol. 6 (2) (1998) 89-97.
13. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M., Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine, Circulation 99 (4) (1999) 552-557.
14. Gan L.S.L., Thakker D.R., Applications of the Caco-2 model in the design and the development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium, Adv. Drug Deliv. Rev. 23 (1997) 77-98.
15. Gottesman M.M., Pastan I., Biochemistery of multidrug resistance mediated by the multi-drug transporter, Annu. Rev. Biochem. 62 (1993) 835-427.
16. Hebert M.F., Fisher R.M., Marsh C.L., Dressler D., Bekersky I., Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers, J. Clin. Pharmacol. 39 (1) (1999) 91-96.
17. Hidalgo I.J., Li J., Carrier-mediated transport and efflux mechanism in Caco-2 cells, Adv. Drug Deliv. Rev. 22 (1996) 53-66.
18. Hochman J.H., Chiba M., Nishime J., Yamazaki M., Lin J.H., Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytocnrome P-450 3A4, J. Pharmacol. Exp. Ther. 292 (1) (2000) 310-318.
19. Hunter J., Hirst B.H., Intestinal secretion of drugs, The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption, Adv. Drug Deliv. Rev. 25 (1997) 129-157.
20. Idriss H.T., Hannun Y.A., Boulpaep E., Basavappa S., Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say!, J. Physiol. 524 (Pt 3) (2000) 629-636.
21. Jolliet-Riant P., Tillement J.P., Drug transfer across the blood-brain barrier and improvement of brain delivery, Fundam. Clin. Pharmacol. 13 (1) (1999) 16-26.
22. Katoh M., Nakapma M., Yamazaki H., Yokoi T., Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport, Eur. J. Pharm. Sci. 12 (4) (2001) 505-513.
23. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R., The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest. 101 (2) (1998) 289-294.
24. Lo A., Burckart G.J., P-glycoprotein and drug therapy in organ transplantation, J. Clin. Pharmacol. 39 (10) (1999) 995-1005.
25. Paulsen I.T., Brown M.H., Skurray R.A., Proton-dependent multi-drug efflux systems, Microbiol. Rev. 60 (4) (1996) 575-608.
26. Rossi J.F., Modulation de la chimio-résistance: méthodologie des essais thérapeutiques, Ann. Biol. Clin. 54 (1996) 25-29.
27. Schwarz U.I., Gramatte T., Krappweis J., Oertel R., Kirch W., P-glycoprotein inhibitor etythromycin increases oral bioavailability of talinolol in humans, Int. J. Clin. Pharmacol. Ther. 38 (4) (2000) 161-167.
28. Seelig A., Blatter X.L., Wohnsland F., Substrate recognition fay P-giycoprotein and the multi-drug resistance-associated protein mrp1: a comparison, Int. J., Clin. Pharmacol. Ther. 38 (3) (2000) 111-121.
29. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.L., Cellular localization of the multi-drug resistance gene product P-glycoprotein in normal human tissues, Proo. Nat Acad. Sci. USA 84 (1987) 7735-7738.
30. Tsuji A., P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier, Ther. Drug Monit. 20 (1998) 588-590.
31. Voshol P.J., Havinga R., Wolters H., Ortenhoff R., Princen H.M., Oude Elferink R.P., Groën A.K., Kuipers F., Reduced plasma cholesterol and increased fecal sterol loss in multi-drug resistance gene 2 P-glycoprotein- deficient mice, Gastroenterology 114 (5) (1998) 1024-1034.
32. Watkins P.B., The barrier function of CYP3A4 and P-glycoprotein in the small bowel, Adv. Drug Deliv. Rev. 27 (1997) 161-170.